Unrelated donor bone marrow transplantation therapy for XXXX .

@entity1 @entity1071 @entity1529 @entity786 @entity1778 @entity2132 @entity1860
Eight @entity1 received allogeneic bone marrow transplantation (BMT) as therapy for @entity1860 ( @entity1860 ) using marrow from unrelated donors. In all cases donors and recipients were HLA DR identical and had low MLC reactivity. In three cases recipients received marrow that was identical at the @entity1529 ,B loci. In five cases HLA identity differed for one @entity1529 locus antigen. The unrelated donor search interval ranged from 2 to 28 months (median, 3 months). All recipients were prepared with a combination of @entity786 , 60 mg/kg/d administered intravenously (IV) (days -6,-5) and with total body irradiation administered in 165 cGy fractions twice daily for four days (days -4, -3, -2, -1). Engraftment occurred in all cases (range, 18 to 48 days; median, 35 days), and return to a complete Philadelphia chromosome (Ph') negative state was documented in six of eight cases. Moderate or severe acute @entity2132 ( @entity2132 ) occurred in seven of eight cases, and extensive chronic @entity2132 in four of six evaluable recipients. A B cell @entity1071 developed in one @entity1 . Four recipients have died within 2 to 4 months of transplant. Four of eight @entity1 survive at 11+ to 24+ months following transplantation (median, 15+ months) with normal peripheral blood counts and without evidence of @entity1778 . Current Karnofsky activity assessments are 90% or 100% in all survivors. Curative therapy of @entity1860 has been available only to the minority of @entity1 eligible for sibling donor BMT. Unrelated donor BMT can be effective in the treatment of @entity1860 and may be particularly useful in this disorder since the prolonged stable phase of disease offers an opportunity to locate suitable donors.
